{'fraction_non_alphanumeric': 0.04476629361421988, 'fraction_numerical': 0.0032916392363396972, 'mean_word_length': 6.378640776699029, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A Dual‐Model Imaging Theragnostic System Based on Mesoporous Silica Nanoparticles for Enhanced Cancer Phototherapy

Mesoporous silica nanoparticles (MSNs) show great promise to be exploited as versatile multifunctional nanocarriers for effective cancer diagnosis and treatment. In this work, perfluorohexane (PFH)‐encapsulated MSNs with indocyanine green (ICG)–polydopamine (PDA) layer and poly(ethylene glycol)–folic acid coating (designated as MSNs‐PFH@PDA‐ICG‐PEG‐FA) are successfully fabricated to achieve tumor ultrasonic (US)/near‐infrared fluorescence (NIRF) imaging as well as photothermal therapy (PTT)/photodynamic therapy (PDT). MSNs‐PFH@PDA‐ICG‐PEG‐FA exhibits good monodispersity with high ICG loading, significantly enhances ICG photostability, and greatly improves cellular uptake. Upon single 808 nm NIR irradiation, the nanocarrier not only efficiently generates hyperthermia to realize PTT, but also produces reactive oxygen species (ROS) for effective PDT. Meanwhile, NIR irradiation can trigger PFH to undergo vaporization and provide a super‐resolution US image. Thus, the PTT/PDT combination therapy can be dually guided by PFH‐induced US imaging and ICG‐induced NIRF imaging. In vivo antitumor studies demonstrate that PTT/PDT from MSNs‐PFH@PDA‐ICG‐PEG‐FA significantly inhibits tumor growth and achieves a cure rate of 60% (three out of five mice are completely cured). Hence, the multifunctional MSNs appear to be a promising theragnostic nanoplatform for multimodal cancer imaging and therapy.